Harvest Ones licensed producer United Greeneries Ltd has received permission from Health Canada to import Satipharms CBD Gelpell® capsules into Canada for research and development purposes.
This allows Harvest One to begin compliance testing and analysis for the Canadian market in anticipation of full-scale production in Canada in 2020.
Initial shipment received
Satipharms CBD Gelpell® capsules are also now available in Argentina for medical purposes and the initial shipment has been received by the first patient.
In March 2017, the Argentine Congress approved a new medical cannabis law which authorises the import of cannabis products for sufferers of refractory epilepsy for patients with a doctors prescription.
Satipharm has signed an agreement with FederalMed to manage the importation and distribution of CBD Gelpell® capsules to patients.
“Key part” of strategy
Harvest Ones CEO Grant Froese said, “At Harvest One, we view the Satipharm CBD Gelpell® capsule as a key part of our health, wellness, and self-care strategy and are very excited to be taking the next step in bringing them to the Canadian market.
“With this import permit, Harvest One can continue the necessary preparations to bring this unique, effective product to Canada.
“We are equally excited to have our first shipment of Satipharms CBD Gelpell® capsules to Argentina, which marks Harvest Ones first entry into South America.
“This adds to our existing distribution which includes 2,000 stores in the UK and Ireland, on-line sales across the EU and prescription sales in Australia.”
Unique CBD capsules
Satipharm produces a CBD capsule using the proprietary Gelpell® process and these capsules take a different approach to other cannabinoid pills on the market in Canada and internationally.
Gelpell® capsules contain full-spectrum hemp extract CBD in seamless gelatine beads.
These microbeads, contained in a hard gastro-resistant capsule, release the CBD in the small intestine and maximise the delivery of CBD to the body.
Manufactured in Switzerland, and GMP certified, every Gelpell® capsule delivers a consistent dose of cannabinoids.
NTA at October 31
MMJ Group, which has a diversified portfolio of cannabis sector investments, has released its net tangible assets (NTA) per share as at October 31, 2019, pursuant to ASX Listing Rule 4.12.
NTA per share as at that date was A30.52 cents pre-tax and A28.53 cents post-tax.
The year to date performance of MMJs NTA.
The company seeks investments across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment, and retail.
One of MMJs key aims is for the share price to trade at a premium to Net Asset Value given the potential returns from portfolio companies which include investments in private cannabis and hemp businesses which are on a short path to public listing or sale of the business.
MMJs investment portfolio as at 31 October 2019.
Seeking NASDAQ listing
Another MMJ Group investment Read More – Source